Donatella Graffino, MD
Allergy · Cedar Knolls, NJNPI 1952302192
Payments from drug & device makers
Across 496 payments — averaging $30.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$7K
- GSK$2K
- Sanofi$2K
- AstraZeneca$1K
- Pfizer$305
- Takeda Pharmaceuticals U.S.A., Inc.$279
- plus $2K from 26 others
What the payments were for
- Consulting fees$190%
- Speaking & faculty fees$7,23047%
- Food & beverage$7,76651%
- Education$2332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 11 | $7,324 |
| GSK | 203 | $2,361 |
| Sanofi | 83 | $1,576 |
| AstraZeneca | 61 | $1,489 |
| Pfizer | 23 | $305 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $279 |
| Amgen | 9 | $202 |
| Sanofi-aventis U.S. LLC | 4 | $202 |
| Optinose US, Inc. | 8 | $191 |
| Bio Products Laboratory USA, Inc. | 7 | $167 |
| CSL Behring | 7 | $143 |
| Regeneron Healthcare Solutions, Inc. | 8 | $138 |
| Alk-abello, Inc | 8 | $106 |
| Genentech USA, Inc. | 7 | $95 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $82 |
| Kaleo, Inc. | 5 | $81 |
| Octapharma USA, Inc. | 4 | $76 |
| Incyte Corporation | 4 | $68 |
| Shire North American Group Inc | 4 | $53 |
| Pharming Healthcare, Inc. | 3 | $51 |
| Novartis | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 3 | $42 |
| Tersera Therapeutics LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| ADMA Biomanufacturing LLC | 1 | $19 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $17 |
| Organon | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,248 in reported general payments places this provider in the 70th percentile of 35 allergy providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 24 | $145,464 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $117,007 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $102,612 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,581 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,281 |
| Arnuity ElliptaFluticasone Furoate | 19 | $3,810 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 31 | $3,607 |
| Epinephrine | 19 | $3,568 |
| AsmanexMometasone Furoate | 12 | $2,796 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,465 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,157 |
| Ipratropium Bromide | 25 | $1,052 |
| Doxepin Hcl | 13 | $986 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $798 |
| Azelastine Hcl | 22 | $656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bio Products Laboratory USA, Inc.Gammaplex | $167 | $145,46424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $279 | $117,00717 claims |
| CSL BehringPrivigen | $143 | $102,61218 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $2,361 | $27,67263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 allergy providers in New Jersey.
Other allergy in Cedar Knolls
- John OppenheimerCedar Knolls$923K
- Jeffrey WeissRiverdale$836K
- Jay KashkinFair Lawn$486K
- Gregory TociMarlton$317K
- Jun YangTinton Falls$213K
- Shashank ShethVoorhees$127K
- Mathew VargheseNorth Bergen$93K
- Eugene GattiMarlton$43K
- Howard DruceSomerville$37K
- Maria Lania-HowarthVoorhees$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.